Skip to main content
XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD. logo

XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 603676 ISIN · CNE100002QQ3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 991 across all filing types
Latest filing 2026-05-27 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603676

About XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD.

http://en.wxkpharma.com/

Xizang Weixinkang Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products, with a primary focus on clinical nutrition and specialized therapeutic areas. The company’s portfolio includes a wide range of multi-vitamin injections, trace element supplements, and electrolyte solutions designed for parenteral administration. It is recognized for its expertise in developing complex formulations, particularly for pediatric and adult patients requiring intensive nutritional support. Key products include multi-vitamin injections for infusion and various specialized chemical drugs. The company emphasizes technological innovation and quality control in its production processes to meet clinical demands for safety and efficacy in hospital settings. Its operations encompass the entire value chain from drug discovery and clinical trials to large-scale production and distribution.

Recent filings

Filing Released Lang Actions
西藏卫信康医药股份有限公司参与认购私募基金份额的公告
Capital/Financing Update Classification · 87% confidence The document is a listed company’s formal announcement detailing its board-approved subscription to a private equity fund with RMB 15 million, including transaction structure, risk disclosures, fund partner details, and capital contribution arrangements. It is neither an earnings/call transcript nor an acquisition/M&A, nor a dividend or management change. It reports on a financing activity (capital allocation/subscription) rather than raising funds, fitting the Capital/Financing Update category (CAP).
2026-05-27 Chinese
广东信达律师事务所关于西藏卫信康医药股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 74% confidence The document is a lawyer’s legal opinion letter attesting to the legality of the convening, participants and vote procedures/results of the 2025 annual shareholders’ meeting. It is not the meeting notice itself nor the full meeting materials (e.g., presentations), but rather a legal attestation. Under the Certification Rule, such attestations and letters by external counsel should be classified as Regulatory Filings (RNS).
2026-05-14 Chinese
西藏卫信康医药股份有限公司独立董事2025年度述职报告（许晓芳）
Regulatory Filings Classification · 82% confidence The document is an "Independent Director 2025 Annual Performance Report" (独立董事 述职报告) by a company’s independent director summarizing board and committee attendance, independence checks, communications, major focus areas, and recommendations. This is neither a financial report (10-K, IR, ER) nor an announcement of board changes (MANG) or remuneration details (DEF 14A), but a mandated regulatory compliance disclosure of an independent director’s duties. It does not fit any specialized category and thus falls under the general “Regulatory Filings” fallback.
2026-04-23 Chinese
西藏卫信康医药股份有限公司关于提请股东会授权董事会制定2026年中期利润分配方案的公告
Proxy Solicitation & Information Statement Classification · 85% confidence The document is an announcement by the board requesting the upcoming shareholders' meeting to authorize the board to formulate a 2026 interim profit distribution (dividend) plan. It provides proposal details, conditions and limits and is intended to solicit shareholder votes at the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), where materials are sent to shareholders to provide information and request votes for a meeting.
2026-04-23 Chinese
西藏卫信康医药股份有限公司董事会关于对独立董事独立性自查情况的专项报告
Governance Information Classification · 82% confidence The document is a board-issued special report assessing the independence of the company’s independent directors under relevant listing and corporate governance rules. It details internal governance compliance (independence criteria and evaluation). This aligns with the Governance Information category rather than an earnings release, capital change, or regulatory notice. Thus, it is classified as Governance Information (CGR).
2026-04-23 Chinese
西藏卫信康医药股份有限公司2025年度审计报告
Regulatory Filings
2026-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.